LOTTE BIOLOGICS Inks CDMO Deal with Ottimo Pharma
Slice of Healthcare Team
06/23/2025
Key highlights
- LOTTE BIOLOGICS to manufacture Jankistomig, an innovative PD1/VEGFR2 dual antibody.
- Manufacturing to take place at Syracuse Bio Campus, New York.
- Supports Ottimo’s IND submission and clinical trials.
- Strengthens LOTTE’s global CDMO presence, spanning North America and Asia.
Source: PR Newswire
Notable Quotes
“ This agreement serves as further validation of our competitiveness as a CDMO in the global antibody therapeutics market. ”
James Park, CEO at LOTTE BIOLOGICS
“ Partnering with Lotte's proven biomanufacturing capabilities enhances our operational readiness and supports our rapid path to IND submission and clinical trial initiation. ”
Joseph Shultz, VP Technical Development & Manufacturing at Ottimo Pharma
Why This Matters
This contract marks a pivotal step in LOTTE BIOLOGICS’s strategic expansion as a leading CDMO, particularly in the field of antibody therapeutics. By partnering with Ottimo Pharma—a company focused on next-generation cancer therapies—LOTTE not only reinforces its manufacturing prowess in North America but also positions itself as a global solution provider across critical therapeutic areas. This collaboration signifies industry confidence in LOTTE’s facilities and operational capabilities, underlining its emergence as a competitive player in the high-demand biologics and ADC sectors.
